Dr. Jahanzeb on the Future of Adjuvant Therapy in HER2+ Breast Cancer

Mohammad Jahanzeb, MD
Published Online: Wednesday, Mar 22, 2017



Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

The mainstay of this disease is HER2 blockade, says Jahanzeb. The future of adjuvant therapy, he adds, is not just a single HER2-targeted agent, but either dual antibody or an antibody followed by a small molecule tyrosine kinase inhibitor.

The chemotherapy that is combined with this is less important, and patients with smaller tumors will not need to be administered combination chemotherapy, says Jahanzeb.
 


Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

The mainstay of this disease is HER2 blockade, says Jahanzeb. The future of adjuvant therapy, he adds, is not just a single HER2-targeted agent, but either dual antibody or an antibody followed by a small molecule tyrosine kinase inhibitor.

The chemotherapy that is combined with this is less important, and patients with smaller tumors will not need to be administered combination chemotherapy, says Jahanzeb.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x